Skip To Main Content
Hobart Rogers on Muck Rack

Hobart Rogers

As seen in: American Journal of Health-System Pharmacy, Drug Metabolism and Disposition (ASPET)
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Hobart

Contact Hobart, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Clinical Pharmacology of RNA Interference-Based Therapeutics: A Summary Based on Food and Drug Administration-Approved Small Interfering RNAs

|
By Vikram Arya, Kellie Reynolds, Hobart Rogers, Xing Jing
| Drug Metabolism and Disposition (ASPET)
Abstract RNA-based oligonucleotide therapeutics are revolutionizing drug development for disease treatment. This class of therapeutics differs from small molecules and protein therapeutics in various ways, including both its mechanism of action and clinical pharmacology characteristics.
Open in Who Shared Issue with article?

Clinical and regulatory considerations in pharmacogenetic testing

|
By Robert N. Schuck, Elizabeth Marek, Hobart Rogers, Michael Pacanowski
| American Journal of Health-System Pharmacy Verified
Purpose Both regulatory science and clinical practice rely on best available scientific data to guide decision-making. However, changes in clinical practice may be driven by numerous other factors such as cost. In this review, we reexamine noteworthy examples where pharmacogenetic testing information was added to drug labeling to explore how the available evidence, potential public health impact, and predictive utility of each pharmacogenetic biomarker impacts clinical uptake.
Open in Who Shared Issue with article?
See all 2 articles